.png)
In silico process to determine the aptamer’s sequence, 3D shape, and affinity, including atomic-level validation of the aptamer’s binding and dynamic behavior.
Computational process allows selection of biomarker’s desired binding region.
.png)
Synthesis constructs an aptamer with known affinity; ensures it does not conflict with other molecules in 3D space.
Folding Validation verifies folding properties of the synthesized aptamer.
Binding Site Validation determines how the aptamer binds to the target, with 3D visualization.
Binding Dynamics and Affinity determines the dynamic affinity to the target.
Cross-Reactivity Assessment predicts if the aptamer reacts with other molecules.
.png)
SELEX is a complex and lengthy iterative process with less than 30% success rate.
Results are limited to affinity; binding sites, morphology and 3D shape remain unknown.
AptaSoft computational synthesis and validation overcomes SELEX’s limitations.
.png)
Aptamers synthesized by AptaSoft replace antibodies in drug delivery applications.
Development of aptamer-drug conjugates can be completed in days, at a fraction of today’s cost.
.png)
Aptamers can be synthesized with optical, electrochemical, chromatic, and magnetic biosensors.
Aptamer biosensors detect and monitor biomarkers, just like antibodies.
Biosensors detect viruses, bacteria, toxins, and other pathogens.
.png)
Aptamers can be synthesized to form molecular imaging probes for use in imaging modalities.
Aptamer imaging probes enhance detection and monitoring of diseases and disorders.
Since aptamer probes can penetrate blood-brain barrier, they are uniquely suitable for use in neurological imaging.
